Drug Profile
THR 317
Alternative Names: Anti-placental growth factor monoclonal antibody; Anti-PlGF; Anti-PlGF monoclonal antibody; R-7334; RG 7334; RO-5323441; TB 403; THR-317; αPlGFLatest Information Update: 09 May 2021
Price :
$50
*
At a glance
- Originator BioInvent International; ThromboGenics
- Developer BioInvent International; Oncurious; Oxurion
- Class Anti-inflammatories; Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Placenta growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy; Glioblastoma; Liver cancer; Medulloblastoma; Retinal telangiectasis; Solid tumours
Most Recent Events
- 12 Apr 2021 Safety, efficacy and pharmacodynamics data from a phase I/IIa trial in Medulloblastoma released by Oncurious NV
- 27 Dec 2019 THR 317 is available for licensing as of 27 Dec 2019. https://www.oxurion.com/ (Oxurion Website, December 2019)
- 19 Dec 2019 Discontinued - Phase-I/II for Medulloblastoma (In adolescents, In children, Second-line therapy or greater) in USA (IV)